Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FE 203799 once-weekly crossover trial in short bowel syndrome with intestinal failure
2017-002486-21Phase 2Completed
- Sponsor
- GLyPharma Therapeutic
- Start
- Nov 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apraglutide in short bowel syndrome (SBS) and intestinal failure (IF) (3 arms), sponsored by GLyPharma Therapeutic. Primary endpoint: Safety and tolerability. Started Nov 2017; status: completed.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)intestinal failure (IF)
Beyond the preview
Go deeper on 2017-002486-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002486-21.